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Elbow trauma can lead to post-traumatic joint contracture (PTJC), which is characterized by
loss of motion associated with capsule/ligament ﬁbrosis and cartilage damage. Unfortunately,
current therapies are often unsuccessful or cause complications. This study aimed to determine
the effects of prophylactically administered simvastatin (SV) and losartan (LS) in two preclinical
models of elbow PTJC: an in vivo elbow-speciﬁc rat injury model and an in vitro collagen gel
contraction assay. The in vivo elbow rat (n  3–10/group) injury model evaluated the effects of
orally administered SV and LS at two dosing strategies [i.e., low dose/high frequency/short
duration (D1) vs. high dose/low frequency/long duration (D2)] on post-mortem elbow range of
motion (via biomechanical testing) as well as capsule ﬁbrosis and cartilage damage (via
histopathology). The in vitro gel contraction assay coupled with live/dead staining (n 
3–19/group) evaluated the effects of SV and LS at various concentrations (i.e., 1, 10,
100 µM) and durations (i.e., continuous, short, or delayed) on the contractibility and viability
of ﬁbroblasts/myoﬁbroblasts [i.e., NIH3T3 ﬁbroblasts with endogenous transforming growth
factor-beta 1 (TGFβ1)]. In vivo, no drug strategy prevented elbow contracture biomechanically.
Histologically, only SV-D2 modestly reduced capsule ﬁbrosis but maintained elevated cellularity
and tissue hypertrophy, and both SV strategies lessened cartilage damage. SV modest beneﬁts
were localized to the anterior region, not the posterior, of the joint. Neither LS strategy had
meaningful beneﬁts in capsule nor cartilage. In vitro, irrespective of the presence of TGFβ1, SV
(≥10 μM) prevented gel contraction partly by decreasing cell viability (100 μM). In contrast, LS
did not prevent gel contraction or affect cell viability. This study demonstrates that SV, but not
LS, might be suitable prophylactic drug therapy in two preclinical models of elbow PTJC.
Results provide initial insight to guide future preclinical studies aimed at preventing or mitigating
elbow PTJC.
Keywords: post-traumatic joint contracture, rat elbow, gel contraction, simvastatin, losartan

Abbreviations: PTJC, post-traumatic joint contracture; SV, simvastatin; LS, losartan; D1, dosing strategy 1 of low dose/high
frequency/short duration; D2, dosing strategy 2 of high dose/low frequency/long duration; SV-D1, simvastatin dosing strategy
1; SV-D2, simvastatin dosing strategy 2; LS-D1, losartan dosing strategy 1; LS-D2, losartan dosing strategy 2; INJ, injury no
drug; Control, uninjured, age-matched; TGFβ1, transforming growth factor-beta 1.
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1 INTRODUCTION

offer potential options because of their pleiotropic effects in
multiple organs and diseases. Classically, SV targets the
mevalonate pathway, which is an essential pathway for cell
health and metabolism (Stancu and Sima, 2001); whereas LS is
an antagonist for the angiotensin II receptor type 1 (Bernasconi
and Nyström, 2018), which modulates the renin-angiotensin
physiologic system. These properties have led to the primary
clinical use of SV and LS to treat hypercholesterolemia and
hypertension, respectively, although these drugs have recently
been considered for treating arthritis due to their potential ability
to suppress inﬂammation in the joint capsule and synovial ﬂuid,
resulting in reduced cartilage damage (Cojocaru et al., 2013;
Veronese et al., 2019; Wu et al., 2019, 2020). Additional
preclinical studies show beneﬁts of administration of both
drugs in other diseases, including cartilage damage and joint
swelling in the knee (Price et al., 2007; Yudoh and Karasawa,
2010; Aktas et al., 2011; Chen R. et al., 2015; Hamilton et al., 2018;
Huard et al., 2018; Utsunomiya et al., 2020; Logan et al., 2021) and
tissue ﬁbrosis in the knee (Baranowski et al., 2019), lungs
(Bagnato et al., 2013; Guo et al., 2015), muscle (Bedair et al.,
2008; Burks et al., 2011; Kobayashi et al., 2013; Davis et al., 2015;
Whitehead et al., 2015; Huard et al., 2018), and heart (Varo et al.,
1999; Spurney et al., 2011; Sun et al., 2015; Böckmann et al., 2019;
Kuo et al., 2019). Collectively, the aforementioned studies in the
knee and other soft-tissues holistically suggest that both drugs
might modulate ﬁbroblasts/myoﬁbroblasts and chondrocytes
biology in the elbow joint post-trauma. Despite these
pleiotropic beneﬁts in other organ-tissues and diseases, both
SV and LS’s impact on elbow PTJC remains unknown.
Therefore, this study aimed to evaluate the effects of SV and LS
in two established preclinical models of contracture. Two SV and
LS dosing strategies were tested in an elbow-speciﬁc rat injury
model in vivo, which normally causes loss of elbow function,
capsule ﬁbrosis, and mild arthritis (Lake et al., 2016; Dunham
et al., 2017a; Dunham et al., 2017b; Dunham et al., 2018a;
Dunham et al., 2018b; Dunham et al., 2019; Dunham et al.,
2020; Dunham et al., 2021; Reiter et al., 2019; Reiter et al., 2021a;
Reiter et al., 2021b). The in vivo model provides translatability of
SV and LS therapy and joint-wide impact on multiple soft tissues
(i.e., capsule and cartilage). Additionally, SV and LS were
evaluated in a collagen gel contraction model in vitro, serving
to mimic elbow capsule contraction in vivo (Hildebrand et al.,
2014). The in vitro model allows for manipulation of
experimental conditions on capsule cells of interest
(i.e., ﬁbroblasts/myoﬁbroblasts). Overall, we hypothesized that
SV and LS would prevent: 1) elbow contracture, capsule ﬁbrosis,
and cartilage damage in vivo; and 2) gel contraction of ﬁbroblasts/
myoﬁbroblasts in vitro.

Elbow trauma can lead to the debilitating condition of post-traumatic
joint contracture (PTJC) in ∼8–50% of afﬂicted elbows (Anakwe
et al., 2011; Myden and Hildebrand, 2011; Monument et al., 2013;
Wessel et al., 2019; Hildebrand et al., 2021). An elbow affected by
PTJC becomes contracted and stiff, leading to reduced range of
motion and function (Anakwe et al., 2011; Myden and Hildebrand,
2011; Monument et al., 2013; Wessel et al., 2019; David et al., 2021;
Hildebrand et al., 2021). Elbow PTJC is largely associated with
capsule ﬁbrosis, but can involve injury to other soft tissues like
muscle, ligament, and cartilage (Monument et al., 2013; David et al.,
2021; Hildebrand et al., 2021; Pooley and Van der Linden, 2021).
When severe elbow PTJC develops, procedures removing the ﬁbrotic
capsule (i.e., capsulotomy) or treating arthritic cartilage (e.g., joint
fusion or arthroplasty) serve as surgical options to improve forearm
function (Monument et al., 2013; David et al., 2021; Hildebrand et al.,
2021; Papadopoulos et al., 2021; Pooley and Van der Linden, 2021).
However, the prognosis of these strategies is largely unpredictable,
and these strategies are often unsuccessful in restoring full-motion/
function and/or are associated with surgical revisions or
complications (Monument et al., 2013; David et al., 2021;
Hildebrand et al., 2021; Papadopoulos et al., 2021; Pooley and
Van der Linden, 2021). Importantly, these approaches fail to
address the biological underpinnings of PTJC, especially during
the immediate-early biological response post-trauma (Monument
et al., 2013; David et al., 2021; Hildebrand et al., 2021). Thus, novel
disease-modifying strategies are needed to prevent or mitigate
elbow PTJC.
Successful preventative treatments for elbow PTJC will likely
depend on the disease severity at the time of intervention and the
soft tissues (e.g., capsule and cartilage) responding to the aberrant
biomechanical and biochemical stimuli post-trauma. Further,
since these stimuli can cause joint-wide changes, it is
important to consider the impact of injury and treatment on
spatial changes in soft tissues at tissue and cellular levels. Similar
to other ﬁbrotic diseases, these aberrant stimuli are thought to
drive a sustained increase in the number of myoﬁbroblasts in the
capsule that contract the tissue and deposit ﬁbrotic matrix (e.g.,
collagen and proteoglycan), leading to ﬁbrosis, stiffness, and loss
of elbow motion (Monument et al., 2013; David et al., 2021;
Hildebrand et al., 2021). In the cartilage, aberrant stimuli posttrauma might drive chondrocytes to overproduce
proinﬂammatory, proﬁbrotic, and catabolic factors, as well as
activate chondrocyte proliferation and death (Zuscik et al., 2008;
Anderson et al., 2011; Goldring, 2012; David et al., 2017).
Consequentially, irreversible changes can occur to cartilage
composition (e.g., loss of proteoglycan) and structure (e.g.,
surface ﬁbrillation), leading to cartilage erosions (Zuscik et al.,
2008; Anderson et al., 2011; Goldring, 2012; David et al., 2017).
Taken together, preventative strategies modulating the
immediate-to-early
injury
response
of
ﬁbroblasts/
myoﬁbroblasts and chondrocytes in the capsule and cartilage,
respectively, will reduce soft tissue damage and elbow
contracture.
In the search for preventative treatments for elbow PTJC, two
FDA-approved drugs, namely simvastatin (SV) and losartan (LS),
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2 METHODS
2.1 In Vivo Rat Elbow Injury Model
2.1.1 Animals, Surgery, and Drug Strategies
In this IACUC-approved study, male Long-Evans rats (n  35;
330–370 g; Charles River Laboratories International,
Wilmington, MA) were subjected to an established elbow
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FIGURE 1 | Experimental design for in vivo rat elbow injury model. (A) Summary of experimental groups, timeline, and post-mortem analysis. Control is uninjured,
age-matched animals. For drug strategies, INJ is an injury with no treatment, while losartan (LS) and simvastatin (SV) represent injury plus LS and SV, respectively;
dosage strategy 1 (D1) and dosing strategy 2 (D2) represents the treatment strategies of low dose/high frequency/short duration vs. high dose/low frequency/long
duration, respectively. (B) Images depicting the ex vivo ﬂexion-extension biomechanical testing set-up and the quantitative angular measurements obtained. In this
elbow injury model, elbow contracture is characterized by i) decrease in the total range of motion, ii) increase in max extension angle (which translates into decreased
elbow extension), and iii) unaltered max ﬂexion. The total range of motion is calculated by determining the angle difference between max extension and max ﬂexion. (C)
Schematic of an elbow mid-sagittal section with the corresponding anatomical location of the capsule and cartilage for histopathology.

2.1.2 Biomechanical Testing
Biomechanical analysis on ex vivo elbows from Control (n  10),
INJ (n  9), D1 (n  5/drug), and D2 (n  3/drug) was performed
as described previously (Lake et al., 2016; Dunham et al., 2017b;
Reiter et al., 2019). Elbows were tested in ﬂexion-extension to
measure the maximum ﬂexion, maximum extension, and range
of motion (ROM), which collectively describe elbow motion
(Figure 1B).

injury model (Lake et al., 2016; Dunham et al., 2017b); male
rats were selected because this PTJC model was developed
using males and few sex-based differences have been observed
(Reiter et al., 2021b). Brieﬂy, unilateral elbows were subjected
to anterior capsulotomy and transection of the lateral
collateral ligament followed by a period of immobilization
(0–42 days post-injury via bandage/wraps) and then free
mobilization (i.e., unrestricted cage activity; 42–84 days
post-injury) (Figure 1A). Immediately after injury, rats
received either no drugs (INJ; n  9) or one of two drug
dosing strategies (D1 or D2; n  3–5/group) administered via
oral gavage: 1) LS-D1; 2) SV-D1; (iii); LS-D2; and 4) SV-D2.
For D1, each drug was given 1x/daily for 3 weeks at 20 mg/kg
and 30 mg/kg for LS and SV, respectively. For D2, each drug
was given 3x/week for 6 weeks at 40 mg/kg and 60 mg/kg for
LS and SV, respectively. Based on previous preclinical studies
(Varo et al., 1999; Bedair et al., 2008; Aktas et al., 2011; Burks
et al., 2011; Spurney et al., 2011; Bagnato et al., 2013;
Kobayashi et al., 2013; Davis et al., 2015; Guo et al., 2015),
the respective low and high doses were chosen, and the dosing
strategies were categorized by either a low dose/high
frequency/short duration (D1) or high dose/low frequency/
long duration (D2); due to the difference in doses for each
drug, no direct comparison between drug-treated groups is
evaluated herein. Oral gavage was chosen as the delivery route
to better control for the drug dose administered at a given
time. Powdered forms of SV and LS were mixed with sterile
water and adjusted for the weight of each rat. Elbows from
uninjured, age-matched rats served as controls (Control; n 
10). After the free mobilization period, rats were humanely
euthanized, and elbows were harvested for post-mortem
biomechanical and histopathological analysis.
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2.1.3 Capsule and Cartilage Histological
Semi-Quantitative Scoring
Following biomechanical testing, elbows (n  3/group) were
histologically processed for parafﬁn embedding, sectioned
(mid-sagittal), and then stained with hematoxylin and eosin
(H&E) and toluidine-blue (Tol-Blue) as previously performed
(Lake et al., 2016; Dunham et al., 2017b, 2018a). Each section
(n  3 sections/stain/elbow) was blinded and semiquantitatively scored by a musculoskeletal histopathologist
(N.H.) using an adaptation of published metrics (BranchetGumila et al., 1999; Lake et al., 2016; Dar et al., 2017; Dunham
et al., 2017b, 2018a). The semi-quantitative assessment of
capsule and cartilage (Supplementary Table S1) included
the characterization of cellular (e.g., cell number and type)
and tissue (e.g., adhesions, ﬁbrosis, thickness, and
proteoglycans) level changes in both anterior and posterior
anatomical joint regions (Figure 1C). For each histological
section, a semi-quantitative metric was derived from a
musculoskeletal
histopathologist
assessment.
After
evaluation, numerical scores for each elbow and group were
averaged, converted into symbolic representation (−, +, ++,
+++, or ++++), and then used for comparisons among groups.
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2.1.4 Cartilage Histomorphometry
Cartilage histomorphometry on the humerus was deployed using
a method derived from previous techniques (Fukui et al., 2014;
Dar et al., 2017; David et al., 2017). Brieﬂy, sections (n  1
representative section/elbow; chosen due to minimal slide to slide
variation in histology scoring) were scanned under identical
settings at 20x magniﬁcation (460 nm/pixel) using the
NanoZoomer 2.0-HT System slide scanner (C9600-12;
Hamamatsu, Shizuoka, Japan). Cartilage regions were deﬁned
in, and exported from, NanoZoomer Digital Pathology software
(NDP-view2, Hamamatsu) and then processed through a semiautomatic script in MATLAB (Mathworks, Natick, MA). The
following parameters were determined within the articular and
calciﬁed cartilages: 1) the number of chondrocytes; 2) the number
of proteoglycan-rich chondrocytes (i.e., chondrocytes with
intense pericellular Tol-Blue+ staining); 3) the number of
empty lacunae; 4) the cartilage area; and 5) the proteoglycanrich cartilage area (Tol-Blue+ staining). To obtain proteoglycanrich cartilage, images were ﬁrst color normalized to account for
histological staining variation (i.e., scaled to each image’s white
background and subchondral bone intensity) and then
thresholded to remove non-proteoglycan rich pixels (based on
average RGB pixel intensities for the subchondral bone).
Proteoglycan amount was quantiﬁed by exploiting Tol-Blue’s
metachromatic staining properties, where a darker Tol-Blue
stain (i.e., lower average RGB pixel intensity) indicates more
proteoglycan (Sridharan and Shankar, 2012).

2 days only (short), or 3) every day after a 2-days delay (delayed)
(Figure 2B; n  3–12 gels/group). These concentrations were
chosen based on previous preclinical work and to test a range of
concentrations several orders of magnitudes apart (Watson et al.,
1998; Fürst et al., 2002; Porter et al., 2004; Watts et al., 2005;
Benoit et al., 2008; Monzack et al., 2009; Burks et al., 2011; Copaja
et al., 2011; Jia et al., 2016; Olschewski et al., 2018). Gels cultured
in drug-free media with and without TGFβ1 served as controls
(n  12–19 gels/group). Culture media was changed every 2 days.
Powdered SV, LS, and TGFβ1 were mixed into culture media
following manufacture guidelines. A subset of gels (n  2–3 gels/
group) in drug-free media were supplemented with only the
reconstitution solvents for SV (i.e., 0.001% dimethyl sulfoxide)
and TGFβ1 (i.e., 0.002 mM hydrochloric acid) to verify that these
solvents without drugs did not alter gel contraction.

2.2.2 Collagen Gel Contraction Dynamics
Gels were imaged daily to monitor changes in gel contraction
(i.e., gel area) by positioning an iPhone 5s (Apple, Cupertino, CA)
below the culture plate resting on a custom-built stand
(Figure 2A). Gel area was quantiﬁed using a custom
MATLAB script, with results shown as a fraction of the initial
gel area (Figure 2B).
2.2.3 Cell Viability in Collagen Gels
After 6 days of continuous drug treatment with or without
TGFβ1, gels (n  4–11 gels/group) were stained with calceinAM (2 μM; Fisher Scientiﬁc, Waltham, MA; FITC ﬁlter cube),
ethidium homodimer-1 (4 μM; Fisher Scientiﬁc; TRITC ﬁlter
cube), and Hoescht (2.5 μg/ml; Fisher Scientiﬁc; DAPI ﬁlter
cube) dyes to identify live, dead, and total cells, respectively
(Figure 2C). Gels were imaged within the gel interior (depths
of ∼40 and ∼100 µm) at ×10 magniﬁcation (PlanFluor DLL 10x
0.30/16.00 mm; Nikon, Calgary, Canada) using an epiﬂuorescent
microscope (BZ-X810; Keyence, Itasca, IL). Cell number and
viability at each gel depth was quantiﬁed and then averaged
to obtain a representative gel value using a custom MATLAB
script.

2.2 In Vitro Gel Contraction and Live/Dead
Assays
2.2.1 Cell and Gel Culture
NIH3T3 ﬁbroblasts (Sigma, St. Louis, MO) and transforming
growth factor-beta one (TGFβ1; R&D Systems, Minneapolis,
MN) were used as the cell line and proﬁbrotic/contraction
stimuli, respectively. This model system is routinely used to
study the transdifferentiation of ﬁbroblasts into myoﬁbroblasts
(Abdalla et al., 2013; Gutiérrez et al., 2015; Negmadjanov et al.,
2015). Further, NIH3T3 ﬁbroblasts were chosen in this study
because primary capsule cells from rat or human tissue are not
easily obtained, isolated, and expanded for high-throughput
analysis. Brieﬂy, NIH3T3 ﬁbroblasts were cultured in media
comprised of DMEM/High Glucose +10% fetal bovine serum
and 1% penicillin-streptomycin (Fisher Scientiﬁc, Waltham,
MA). Upon reaching ∼80% conﬂuency, NIH3T3 ﬁbroblasts
were trypsinized and mixed into neutralized (pH 7; 300
mOsm) rat-tail collagen solution (collagen concentration of
1.5 mg/ml) at a density of 5 × 105 cells/ml following previous
methods (Cross et al., 2010; Iannucci et al., 2019). The collagencell mixture (500 µL) was then cast into uncoated 24-well plates
(Midwest Scientiﬁc, Valley Park, MO) and polymerized for 1 h at
37°C before adding fresh media. After 24 h, gels were released
from the wells using a sterile spatula to initiate spontaneous, freeﬂoating gel contraction (Figure 2A). Immediately after releasing
gels, SV or LS was added (1, 10, or 100 µM) with and without
TGFβ1 (10 ng/ml) 1) every day (continuous), 2) for the ﬁrst
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2.3 Statistics
Biomechanical data for INJ and Control were published
previously and included for comparison (Reiter et al., 2019)
but their histological sections were subjected to the analysis
protocol herein (Dunham et al., 2017b). Statistical analysis was
performed using GraphPad Prism 9 (GraphPad Software, San
Diego, CA). For in vivo data, one-way ANOVA with Dunnett’s
post-hoc test was performed to detect differences in
biomechanical and cartilage histomorphometry parameters
between INJ and drug-treated groups compared to Control. Of
note, samples from LS-D2 were excluded from semi-quantitative
scoring (n  1) and histomorphometry (n  2) because of
histological processing errors and section folding. For in vitro
data analysis, one-way ANOVA with Dunnett’s post-hoc test
(against the respective drug-free condition) was performed for
each parameter. Statistical signiﬁcance was set at p ≤ 0.05, while
trends were identiﬁed as 0.05 < p ≤ 0.10.
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FIGURE 2 | Experimental design for in vitro NIH3T3 ﬁbroblast-embedded gel contraction. (A) Imaging set-up used to monitor gel contraction. Representative
images of collagen gel (1.5 mg/ml) contraction by embedded NIH3T3 ﬁbroblasts (5 × 105 cells/ml) with and without TGFβ1 (10 ng/ml) over time. Note: Day 0 is not shown
as the gels are approximately the same size as the well, and intermediate timepoints are sizes in between the days shown. (B) Quantiﬁcation of gel contraction and drug
dosing strategies used. Results are shown as average ± SEM (n  12 for No TGFβ1; n  19 for + TGFβ1). Note: star  live/dead assay. (C) Representative images of
live, dead, and total cell staining used to quantify cell number (# of nuclei) and viability (% viable).

FIGURE 3 | No drug strategy prevented biomechanical measures of elbow contracture. Biomechanical parameters of decreased range of motion (A) and
increased max extension (i.e., decreased elbow extension) (B) demonstrate signiﬁcant elbow contracture in all groups compared to Control; no treatment strategy
prevented or improved elbow contracture. Max ﬂexion (C) was largely unaffected by injury and treatment compared to Control. Results are shown as average ± SD; #
indicates p < 0.05 signiﬁcant difference from Control (one way-ANOVA with Dunnett’s post-hoc). Note: Control  uninjured, age-matched; INJ  injury no drug; LSD1  losartan dosing strategy 1; LS-D2  losartan dosing strategy 2; SV-D1  simvastatin dosing strategy 1; and SV-D2  simvastatin dosing strategy 2.

3 RESULTS

3.1.2 Anterior and Posterior Capsule Histopathology
Histopathology analysis revealed that all groups displayed
different injury-induced responses at the tissue and cellular
level in both the anterior (Table 1; Figure 4) and posterior
(Table 1; Supplementary Figure S1) capsule. In the anterior
capsule, INJ increased tissue-level parameters of capsule
thickness, ﬁbrosis, adhesion, and proteoglycans compared to
Control (Table 1; Figure 4). With both LS treatments, similar
tissue-level changes occurred in the INJ, except both resulted in a
thickened, more ﬁbrotic anterior capsule; LS-D2 also slightly
reduced proteoglycans (Table 1; Figure 4). Similarly, both SV
treatments had a different response to that observed in INJ
(Table 1; Figure 4). SV-D2 slightly reduced ﬁbrosis,
proteoglycans, and adhesions compared to INJ, although these
metrics were still elevated compared to Control (Table 1;

3.1 In Vivo Rat Injury Model
3.1.1 Rat Health and Elbow Biomechanics
No visible adverse side effects assessed by a veterinarian nor
differences in rat weights among groups were observed (data not
shown). Biomechanical testing revealed signiﬁcantly decreased elbow
range of motion (∼22%; Figure 3A) and extension motion (i.e., larger
maximum extension values; ∼145%; Figure 3B) in INJ compared to
Control. All drug strategies displayed similar changes in the range of
motion and extension motion as in INJ compared to Control
(Figures 3A,B). There were no differences in maximum ﬂexion
between any experimental group and Control except for LS-D1 (∼5%;
Figure 3C). These biomechanics results indicate elbow contracture is
not mitigated by drug treatments.

Frontiers in Bioengineering and Biotechnology | www.frontiersin.org
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TABLE 1 | Histological semi-quantitative scoring of the anterior and posterior capsule highlighted altered tissue and cellular properties post-injury and treatment. In the anterior
capsule, INJ induced tissue-level thickening, proteoglycan deposition, and development of ﬁbrosis and adhesions; SV-D2 is the only treatment that modestly reduced
proteoglycans, adhesions, and ﬁbrosis, albeit with increased tissue thickness, cellularity (predominantly ﬁbroblasts/myoﬁbroblasts), and synovial proliferation. Similar observations
were made in the posterior capsule; however, SV-D2 no longer had capsular beneﬁts in reducing tissue ﬁbrosis, adhesions, or proteoglycans. In both anterior and posterior
capsules, there was no change in vascularity or the number of mast cells and mononuclear inﬂammatory cells in any group compared to Control. Note: Histological
parameters were semi-quantitatively assessed and given a symbol of either −, +, ++, +++, or ++++, where increases in the number of symbols (+vs. ++++) indicate worse
disease severity; details on grading scheme is found in Supplementary Table S1; Control  uninjured, age-matched; INJ  injury no drug; LS-D1  losartan dosing strategy
1; LS-D2  losartan dosing strategy 2; SV-D1  simvastatin dosing strategy 1; and SV-D2  simvastatin dosing strategy 2.
Level

Parameter

Tissue

Thickness
Adhesions
Fibrosis
Proteoglycan Amount
Vascularity

Cellular

Cellularity
Synovial Proliferation
Fibroblasts/myoﬁbrobasts
Mast Cells
Mononuclear Inﬂammatory Cells

Anterior Capsule

Posterior Capsule

Control
−
−
−
−
+

INJ
++
++
++
+
+

LS-D1
++++
++
+++
+
+

LS-D2
+++
++
++
−
+

SV-D1
++
++
++
+
+

SV-D2
++
+
+
−
+

Control
+
−
−
−
+

INJ
+++
++
++
+
+

LS-D1
+++
+++
++
+
+

LS-D2
++++
+++
++
++
+

SV-D1
++++
+++
+++
+
+

SV-D2
++++
+++
+++
+
+

+
−
+
+
+

+
−
+
+
+

+++
+
+++
+
+

++
+
++
+
+

+++
+
+++
+
+

++
+
++
+
+

+
−
+
+
+

+
+
+
+
+

+++
+
++
+
+

++
+
+
+
+

+++
+
++
+
+

++
+
++
+
+

FIGURE 4 | SV, but not LS, modestly reduced capsule ﬁbrosis anteriorly, albeit with increased tissue thickness and cellularity. Qualitative histopathology
assessment on H&E midsagittal sections of the anterior capsule highlights changes in the overall capsule tissue and cellular morphology. Control capsule displays loosely
packed and disorganized tissue with minimal cellularity, whereas injury caused thickened tissue and ﬁbrosis with minimal cells. Treatments displayed increased
thickness, cellularity (mostly ﬁbroblasts/myoﬁbroblasts), synovial proliferation (arrows), and ﬁbrosis. However, SV-D2 was the only group able to modestly reduce
capsule ﬁbrosis (open star). Note: H  humerus; R  radius; Control  uninjured, age-matched; INJ  injury no drug; LS-D1  losartan dosing strategy 1; LS-D2  losartan
dosing strategy 2; SV-D1  simvastatin dosing strategy 1; and SV-D2  simvastatin dosing strategy 2.

Figure 4). There was no change in vascularity between groups
(Table 1).
At the cellular level of the anterior capsule, no differences were
observed in total cellularity, synovial proliferation, and types of
cells (ﬁbroblasts/myoﬁbroblasts, mast cells, or mononuclear
inﬂammatory) in INJ compared to Control (Table 1;
Figure 4). In contrast, every drug strategy led to increased
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cellularity,
ﬁbroblasts/myoﬁbroblasts,
and
synovial
proliferation compared to Control (Table 1; Figure 4). No
drug strategy resulted in changes to mast or mononuclear
inﬂammatory cells at the time point evaluated (Table 1).
For the posterior capsule, every drug strategy exhibited similar
trends but increased scores at the tissue and cellular level compared to
the anterior capsule (Table 1; Supplementary Figure S1). Notably,
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FIGURE 5 | SV, but not LS, reduced cartilage surface irregularities and enhanced proteoglycan content anteriorly. (A) Qualitative histopathology assessment on
toluidine blue (Tol-Blue) and hematoxylin and eosin (H&E) midsagittal sections of anterior humerus articular cartilage (AC) and calciﬁed cartilage (CC) demonstrate minor
cartilage surface-level ﬁbrillations (white-ﬁlled arrow) with injury alone (INJ) compared to Control. Treatment with either LS strategy caused worse visible structural and
modest proteoglycan loss (asterisks) changes. In contrast, both SV treatments appeared to reduce the severity of this damage and increased cartilage thickness,
proteoglycan content, and proteoglycan-rich chondrocytes (black-ﬁlled arrow), as seen in Tol-Blue images. Note the minor loss of chondrocytes (blue circle) and the
drastic change in chondrocyte morphology with an enlargement (open arrow) and cloning/clustering (blue-ﬁlled arrow) of chondrocytes in the articular cartilage, as seen
in H&E images. (B–F) Quantitative cartilage histomorphometry of the humerus articular cartilage at the tissue level largely conﬁrms these qualitative assessments while
providing additional insight into cellular level changes in the number of chondrocytes and those with enriched pericellular proteoglycan. Results are shown as mean ± SD;
# indicates p ≤ 0.05 signiﬁcant difference and * indicates 0.05 < p ≤ 0.10 trending signiﬁcance from Control (one-way ANOVA with Dunnett’s post-hoc). Note: Control 
uninjured, age-matched; INJ  injury no drug; LS-D1  losartan dosing strategy 1; LS-D2  losartan dosing strategy 2; SV-D1  simvastatin dosing strategy 1; and SV-D2
 simvastatin dosing strategy 2.

TABLE 2 | Histological semi-quantitative scoring of the anterior and posterior cartilage demonstrated altered tissue and cellular properties post-injury and treatment. In both
anterior and posterior cartilage, INJ caused minor surface irregularities compared to Control. In the anterior cartilage, both SV strategies could slightly prevent these
minor surface irregularities, whereas LS had no beneﬁt and even caused a loss of proteoglycan matrix staining. Posteriorly, no strategy provided cartilage protection; in fact,
SV strategies worsened the severity of cartilage damage. Note: Histological parameters were semi-quantitatively assessed and given a symbol of either −, +, ++, +++, or
++++, where increases in the number of symbols (+vs. ++++) indicate worse disease severity; details on grading scheme is found in Supplementary Table S1;
Control  uninjured, age-matched; INJ  injury no drug; LS-D1  losartan dosing strategy 1; LS-D2  losartan dosing strategy 2; SV-D1  simvastatin dosing strategy 1;
and SV-D2  simvastatin dosing strategy 2.
Level

Parameter

Tissue

Structural Damage
Proteoglycan Loss
Tidemark Integrity

Cellular

Cellularity

Anterior Cartilage

Posterior Cartilage

Control
−
−
−

INJ
+
−
−

LS-D1
+
+
−

LS-D2
+
+
−

SV-D1
−
−
−

SV-D2
−
−
−

Control
−
−
−

INJ
+
+
−

LS-D1
+
+
−

LS-D2
+
+
−

SV-D1
+
+
−

SV-D2
++
+
−

−

−

−

−

−

−

−

−

−

+

−

−

SV-D2 did not reduce ﬁbrosis and adhesions in the posterior capsule
as was seen in the anterior capsule (Table 1; Supplementary Figure
S1). Collectively, these results indicate that only SV had modest
beneﬁts in capsule pathology (i.e., decreased ﬁbrosis, adhesions, and
thickening) through modulating the population of ﬁbroblasts/
myoﬁbroblasts in the anterior region and not the posterior region.
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3.1.3 Anterior and Posterior Cartilage Histopathology
Histopathology assessment of the cartilage highlighted drastic
changes at the tissue and cellular level depending on the
anatomical location and the drug strategy. In the anterior
region of INJ compared to Control, qualitative (Figure 5A)
and semi-quantitative scores (Table 2) revealed mild cartilage
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3.2 In Vitro Gel Contraction

damage in the form of surface irregularities, but without either a
loss of proteoglycans, compromise in the tidemark integrity, or
cellular morphological changes. Both LS strategies had a similar
level of cartilage damage as INJ, except there was an additional
loss of proteoglycans (Table 2; Figure 5A). On the contrary, SVtreated groups showed modestly reduced cartilage damage
(Table 2; Figure 5A). While semi-quantitative metrics
indicated no drastic changes in chondrocyte cellularity across
entire cartilage (Table 2), qualitatively it appeared that injury
with or without drug treatments induced subtle yet notable
localized cellular morphology changes in the articular cartilage
of the humerus (Figure 5A). Chondrocyte hypertrophy and
cloning/clustering was observed in localized regions in INJ
compared to Control (Figure 5A). For treatments,
chondrocytes were somewhat absent in both LS groups
while being enlarged and displaying clustering/cloning in
both SV strategies (Figure 5A). Histomorphometry of the
humerus cartilage revealed that INJ did not alter any
parameter compared to Control (Figures 5B–F). However,
SV strategies largely increased the overall cartilage area
(Figure 5B), the distribution (i.e., area; Figure 5C) and
amount (i.e., staining intensity; Figure 5D) of
proteoglycan, and the number of proteoglycan-rich
chondrocytes (Figure 5E). In contrast, LS strategies exerted
no appreciable changes. For all groups, no appreciable
changes in humerus cartilage histomorphometry were seen
in the number of chondrocytes (Figure 5F) and empty lacunae
(data not shown) in the articular cartilage or in any metric in
the calciﬁed cartilage (data not shown).
Histopathology assessment of the posterior cartilage
revealed mostly similar observations to the anterior
cartilage. Qualitative (Supplementary Figure S2A) and
semi-quantitative analyses (Table 2) showed posterior
cartilage damage in INJ and both LS treatment groups
compared to Control, including surface ﬁbrillations and
loss of proteoglycans; additional diffuse hypercellularity
was seen in the LS-D2 group. Contrary to semi-quantitative
observations in the anterior cartilage, both SV strategies
caused signiﬁcant cartilage erosions and loss of
proteoglycan in the posterior region (Table 2). Qualitative
assessment did not reveal striking changes in chondrocyte
morphology in most groups, except the slight appearance of
empty lacunae with both SV strategies (Supplementary
Figure S2A). Articular cartilage histomorphometry
(Supplementary Figures S2B–F) largely conﬁrmed these
qualitative and semi-quantitative observations with no
changes in any parameter evaluated; however, despite
erosions and loss of proteoglycan observed qualitatively
and semi-quantitatively, there was no overall change in
cartilage area or proteoglycans quantitatively. No
appreciable
cellular
and
tissue-level
cartilage
histomorphometry changes were observed in the posterior
calciﬁed cartilage (data not shown). Taken together, these
results indicate that only SV had modest cartilage protection
anteriorly through changes in chondrocyte appearance and
extracellular matrix of the articular cartilage and not calciﬁed
cartilage.
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3.2.1 Fibroblasts/Myoﬁbroblasts Cell Contractility and
Viability
In vitro studies detected differences across groups in the degree of
gel contraction (Figures 6A–C). On day 6 of culture, drug-free
gels decreased in area from the initial size without (∼30%) and
with (∼95%) TGFβ1 (Figures 6A,B). Irrespective of TGFβ1,
continuous SV treatment prevented (i.e., no decreased area;
Figures 6A,B) gel contraction at concentrations ≥10 µM
compared to drug-free control. In contrast, no concentration
of LS prevented gel contraction. Since only SV prevented gel
contraction, a subset of SV- and TGFβ1-treated only gels were
used to test the effect of timing and duration of SV. Similar
inhibition of contraction occurred if SV was delayed and given for
a short duration (Figure 6C); however, 10 µM SV no longer
inhibited contraction if applied for a short duration. On day 6
after continuous drug treatment with and without TGFβ1,
100 µM SV signiﬁcantly reduced cell number (∼70–80%;
Figures 6D,E) and viability (∼35–45%; Figures 6F,G). In a
subset of gels, there was no impact of reconstitution solvents
for SV and TGFβ1 on gel contraction (Supplementary Figure
S3). Overall, these results indicate that only SV could prevent gel
contraction at moderate to high concentrations through
modulation of NIH3T3 ﬁbroblasts/myoﬁbroblasts health and
contractility.

4 DISCUSSION
4.1 Overview
Currently, an unmet clinical need exists for novel therapies to
prevent the development of elbow PTJC. Thus, this study tested
the effects of prophylactically administered SV and LS in two
preclinical models of elbow PTJC. In the rat elbow PTJC model in
vivo, SV and LS did not prevent the onset of elbow contracture as
indicated from post-mortem biomechanics (Figure 3). However,
both drugs modulated capsule and cartilage biology on a regiondependent cellular and tissue level as indicated histologically
(Tables 1, 2; Figures 4, 5; Supplementary Figures S1, S2). SV
drug delivery appeared to decrease capsule ﬁbrosis and cartilage
damage in the joint anteriorly, yet increased damage severity in
the posterior region. This observed location-dependent
phenotype suggests a complex injury-drug response by which
altering the anterior region of the joint with drugs might impact
the biological activity in multiple tissues throughout the elbow.
Neither LS dose showed any beneﬁts and appeared to increase
disease severity in both cartilage and capsule. In vitro,
concentrations of SV, but not LS, inhibited ﬁbroblasts/
myoﬁbroblast contractility (Figure 6). Considering the in vitro
and in vivo data together suggests that both SV and LS can
modulate the biological activity and tissue-level properties of
capsule and cartilage. However, it appears that drug-induced
cellular and tissue level changes do not necessarily translate to the
functional level, at least at the single timepoint evaluated, which
might have implications for future clinical and preclinical studies
of elbow PTJC. Overall, these data provide a foundation of
knowledge to understand better SV and LS potential as
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FIGURE 6 | SV, but not LS, reduced ﬁbroblasts/myoﬁbroblasts contractility and viability in vitro. (A–C) Quantitative assessment of gel contraction area
demonstrated that continuous, delayed, and short application of SV, but not LS, reduced contraction without and with TGFβ1 after 6 days. (D–G) Assessment of cell
number and viability demonstrated that only continuous 100 µM SV treatment reduced cell number and viability without and with TGFβ1 after 6 days. Results are shown
as mean ± SD; # indicates p < 0.05 signiﬁcant difference from drug-free controls (one way-ANOVA with Dunnett’s post-hoc).

disease-modifying drugs for elbow PTJC and to guide the future
optimization of dosing and delivery strategies.

monocytes and mast cells) that are commonly implicated in knee
contracture (Monument et al., 2013; David et al., 2021), yet shifts in
these cell populations could occur at other timepoints post-injury or
the signaling between such cells might be altered. It is unclear why
SV’s effects were localized anteriorly; however, since the anterior
capsule is the primary tissue of interest driving elbow contracture in
this model and clinically, the increased disease severity in the
posterior joint location may not be as critical. Despite modest
beneﬁts of SV, LS given at either dosing strategy 1 (20 mg/kg
given daily for 3 weeks) or strategy 2 (40 mg/kg given 3 days/week
for 6 weeks) failed to decrease the severity of capsule ﬁbrosis, cartilage
damage, or contracture. Given the limited timepoints following
trauma and drug therapies assessed herein, it remains unknown if
decreased capsule ﬁbrosis, adhesions, and proteoglycans associated
with elevated tissue thickness and cellularity indicates a delay or
reduction in capsule ﬁbrosis or tissue regeneration.
Since limited knowledge exists regarding elbow speciﬁc PTJC,
as well as the use of SV and LS for PTJC in other musculoskeletal

4.2 SV and LS Induces Pleiotropic Effects on
Capsule Biology In Vivo

Elbow PTJC is primarily driven by capsule ﬁbrosis; hence, a study
goal was to prevent capsule ﬁbrosis post-trauma, particularly in the
anterior region of the elbow since it is the location where the
surgically induced injury occurs in the in vivo model (Lake et al.,
2016; Dunham et al., 2017b). Indeed, SV given at dosing strategy 2
(60 mg/kg given 3 days/wk for 6 weeks), but not dosing strategy 1
(30 mg/kg given daily for 3 weeks), modestly reduced anterior capsule
ﬁbrosis/adhesions, although the capsule was still thick and displayed
increased cellularity compared to Control (Figure 4; Table 1). At the
cellular level, ﬁbroblasts and/or myoﬁbroblasts were histologically
identiﬁed as the predominant cell type in the capsule at the timepoint
evaluated (Table 1). This is in opposition to inﬂammatory cells (e.g.,
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joints (e.g., knee), careful considerations should be taken when
comparing this study to the literature. Nevertheless, our mixed
multi-scale results somewhat align with a study by Baranowski
et al., that evaluated the effects of orally administered losartan
(30 mg/kg/day) and statins (in this case, atorvastatin; 15 mg/kg/
day) on capsule ﬁbrosis and joint contracture in a rat knee model
of PTJC (Baranowski et al., 2019). Similar to our results, they
found no functional beneﬁt, yet both drugs still altered the
capsule tissue and cellular properties. At the tissue level,
atorvastatin and LS decreased and increased capsular
thickness, respectively, while both drugs reduced the total
cellularity and proportion of myoﬁbroblasts at the cellular
level. The efﬁcacy discrepancy between studies could be due to
the joint type, soft-tissue damage from traumatic injury, dosing
strategies, timepoints evaluated, or analysis technique.
Nevertheless, it appears that SV and LS can modulate the
capsule’s biological activity and tissue-level properties of the
elbow in a dosing strategy and anatomical location-dependent
manner.

2011; Spurney et al., 2011; Bagnato et al., 2013; Kobayashi et al.,
2013; Guo et al., 2015; Huard et al., 2018; Baranowski et al., 2019;
Böckmann et al., 2019). Other studies have reported similarly
mixed effects, where LS inhibited gel contraction in some culture
conditions (Watson et al., 1998; Benoit et al., 2008; Jia et al., 2016)
yet also increased cell adhesions/invasion and proliferation
(Olschewski et al., 2018). Such mixed results could be due to
in vitro vs. in vivo study designs, culture conditions (e.g., collagen
and cellular densities), cell type (e.g., primary vs. cell line), use of a
single proﬁbrotic factor (e.g., TGFβ1 vs. angiotensin II) and/or
the presence of LS target receptor [i.e., angiotensin II type 1,
which NIH3T3 ﬁbroblasts minimally express (Heemskerk et al.,
1999; De Paolis et al., 2002)]. In a subset of separate gels,
angiotensin II (i.e., 10 and 100 ng/ml) was applied and had no
impact on gel contraction (Supplementary Figure S3),
suggesting a minimal inﬂuence of angiotensin II on NIH3T3
ﬁbroblasts/myoﬁbroblasts contractility. However, angiotensin II
and LS might exert effects in other cellular activity of NIH3T3
ﬁbroblasts/myoﬁbroblasts that extend beyond gel contraction
studied herein (e.g., production of growth factors/cytokines,
proliferation, and adhesions/invasion). Collectively, these
in vitro ﬁndings suggest SV, but not LS, can directly modulate
cellular contractility and health of ﬁbroblasts/myoﬁbroblasts
embedded within collagen gels, but whether SV can directly
impact these cellular processes in vivo remains unknown.

4.3 SV, but not LS, Prevents Fibroblasts/
Myoﬁbroblasts-Mediated Gel Contraction
In Vitro
In this study, the gel contraction model utilizing NIH3T3
ﬁbroblasts and TGFβ1 as a proﬁbrotic factor (Abdalla et al.,
2013; Gutiérrez et al., 2015; Negmadjanov et al., 2015) was
performed to simulate in vivo capsule contraction (Hildebrand
et al., 2014) and evaluate SV and LS’s direct effects on ﬁbroblasts
and myoﬁbroblasts. SV, but not LS, reduced gel contraction
under conditions with and without TGFβ1 in NIH3T3
ﬁbroblasts/myoﬁbroblasts (Figure 6). SV at higher
concentration (100 µM) inhibited gel contraction mostly due
to cell death, while SV at a moderate concentration (10 µM)
likely altered cell contractility (assessed via extent of gel
contraction; Figure 6). Notably, the effects of SV were
transient because the gel contraction response was not altered
when SV was only given for a short duration (Figure 6). Delayed
application of SV (≥10 µM) led to a complete halt in gel
contraction, albeit with about ∼60% contraction still occurring
prior to applying SV (Figure 6). Generally, our results align with
SV’s known inﬂuence on the mevalonate pathway (Stancu and
Sima, 2001) and ﬁbroblasts/myoﬁbroblasts (i.e., reduced
proliferation, viability, and contractility with ≤10 µM) (Fürst
et al., 2002; Porter et al., 2004; Watts et al., 2005; Monzack
et al., 2009; Burks et al., 2011; Copaja et al., 2011; Kuo et al., 2019).
Further, our in vitro gel ﬁndings might explain/support the ability
of SV to have a potential reduction in anterior capsule ﬁbrosis by
modulating
ﬁbroblasts/myoﬁbroblasts
phenotype
(i.e., contractility), metabolism (e.g., deposition of ﬁbrotic
matrix), and signaling (e.g., autocrine/paracrine signaling).
However, given the systemic administration of drugs in this
study, SV’s impacts in vivo might extend beyond the direct
effects on ﬁbroblasts/myoﬁbroblasts observed in vitro (e.g.,
modulating inﬂammatory cell health and signaling).
Surprisingly, LS did not reduce gel contraction in vitro despite
its known anti-ﬁbrotic properties (Bedair et al., 2008; Burks et al.,
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4.4 SV and LS Induces Pleiotropic Effects on
Cartilage Biology In Vivo
Elbow trauma can cause damage to other soft tissues in the elbow
like cartilage; hence, this study evaluated changes to cartilage in
the rat injury model of elbow post-trauma. Similar to the capsule,
cartilage exhibited location- and drug-dependent changes. In
both the joint’s anterior and posterior region, all cartilage
changes occurred in the articular and not calciﬁed cartilage,
suggesting direct and localized effects to chondrocytes in the
articular cartilage; however, this does not rule out the possibility
of intracellular signaling between articular and calciﬁed cartilage
with other elbow tissues such as the capsule or subchondral bone.
In both the anterior and posterior region, injury alone caused
mild surface ﬁbrillations/irregularities (Table 2; Figure 5;
Supplementary Figure S2). Surface irregularities in the
posterior region was unexpected since the injury model herein
causes soft tissue damage to the anterior region of the joint (Lake
et al., 2016; Dunham et al., 2017b); this suggests joint-wide
changes not previously appreciated in this injury model of
PTJC. With treatments, cartilage damage in the anterior
region was slightly prevented (e.g., reduced surface
irregularities/ﬁbrillation) with both SV strategies, whereas both
LS strategies caused further damage (e.g., erosions) (Table 2;
Figure 5). There were notable focal regions of chondrocytes in SV
treated groups that displayed enhanced clustering (Figure 5A),
though this was not a widespread phenomenon across all
articular cartilage. Collectively, histological observations of SV
cartilage protection might be due to an overall increase in
cartilage area combined with enhanced proteoglycan matrix
composition in both the extracellular and pericellular matrices
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around chondrocytes (Figure 5). These observations in SVtreated joints suggest chondrocyte-driven attempts to repair,
regeneration, and/or anabolism (Zuscik et al., 2008; Anderson
et al., 2011; Goldring, 2012). However, since only one time point
was evaluated post-trauma, it is unclear if this chondrocyte
response would continue to be beneﬁcial long term. Despite
providing modest beneﬁts anteriorly, both SV strategies led to
articular cartilage erosions posteriorly (Table 2; Supplementary
Figure S2). Although erosions developed, histomorphometric
analysis revealed that the total cartilage area did not change;
suggesting that the remaining non-eroded articular cartilage
increases in area, as seen anteriorly, and could indicate tissue
adaptation. Contrary to SV, LS was unable to provide any surfacelevel protection and led to areas devoid of chondrocytes (Table 2;
Supplementary Figure S2).
Given the limited a priori knowledge of elbow-speciﬁc
cartilage biology, studies from the literature utilizing SV and
LS for preventing arthritis in other joints (e.g., the knee) can help
interpret this study’s ﬁndings. For example, SV is thought to
prevent cartilage damage by enhancing chondrogenesis (e.g.,
increased proteoglycan synthesis) and reducing chondrocyte
production of harmful biochemical factors (e.g., inﬂammatory
cytokines and matrix-degrading enzymes) (Yudoh and Karasawa,
2010; Aktas et al., 2011). LS appears to provide similar cartilage
structure protection in the knee (Chen R. et al., 2015; Huard et al.,
2018; Utsunomiya et al., 2020; Logan et al., 2021) but can also
accelerate chondrocyte enlargement/hypertrophy in the growth
plate (Chen S. et al., 2015). Contrary to the structural/
composition beneﬁts (e.g., prevention of ﬁbrillations and
erosions) of drug treatment on cartilage seen in these previous
preclinical studies, there was no robust tissue-level improvement
with most SV and LS strategies in this study. However, recent
work has shown LS at higher dosages can halt cartilage repair and
induce cartilage damage in healthy cartilage (Logan et al., 2021),
which somewhat aligns with the deleterious effects of LS strategies
in this study. Collectively, these discrepancies could be due to the
dosing strategy, joint location (e.g., anterior vs. posterior), joint
studied (e.g., elbow vs. knee), type of arthritis (e.g., rheumatoid
arthritis vs. post-trauma osteoarthritis), and type of traumatic
insult (e.g., trauma, immobilization, chemical, or combinations).
Furthermore, it is unclear whether the cartilage response was
directly or indirectly modulated by capsule biology, or vice versa.
Nevertheless, our ﬁndings suggest that SV and LS impact the
chondrocyte/cartilage injury response, but the full extent of these
drugs’ impact on cartilage requires further investigations.

effect of drug treatment in female rats could be different and should
be considered. Since drugs were given systemically, knowledge about
the pharmacokinetics and bioavailability of drugs within the elbow’s
synovial space would be critical for understanding the drug
mechanisms of action and optimizing and choosing alternative
dosing and delivery strategies (e.g., use of nanoparticles, intraarticular injections, drinking water, or topical application). It is
also important to consider that the bioavailability and effects of
each drug herein and using alternative dosing and delivery strategies
could also be impacted by the in vivo half-life of each drug [e.g., about
1–5 h in humans (MacDonald and Halleck, 2004; Schachter, 2005;
Sica et al., 2005)]. Additionally, in vivo work should also evaluate drug
concentrations and critical biomarkers of disease (e.g., TGFβ1, matrix
degrading enzymes, and proinﬂammatory cytokines assessed via
immunohistochemistry or other analysis techniques) in the
cartilage and capsule, as well as the elbow’s synovial space and
systemic blood serum. Beyond future in vivo work, the in vitro gel
contraction assay would be more impactful if primary cells from the
elbow capsule are used and co-culture studies are performed using
other cells (e.g., macrophages and mast cells) that might
communicate to ﬁbroblasts/myoﬁbroblasts in vivo (Monument
et al., 2013; Hildebrand et al., 2014). Finally, understanding the
underlying drug mechanism(s) driving capsule and cartilage
biology changes will prove vital to fully determining the
therapeutic potential of these treatment strategies.

5 CONCLUSION
In conclusion, this study demonstrated that SV, but not LS, can
prevent capsule ﬁbrosis and cartilage damage in vivo and cell
contractility in vitro. In the rat elbow contracture model, orally
administered SV altered histopathological evaluations at the
cellular and tissue level in the capsule and cartilage but did
not ultimately improve joint function at the single time point
evaluated. In the gel contraction assay, SV transiently altered
ﬁbroblasts/myoﬁbroblasts contractility. Both preclinical models
demonstrated that the success of SV as a treatment for elbow
PTJC will be dependent on the dosing strategy. Unfortunately, LS
did not elicit a beneﬁcial change in either the in vivo or in vitro
system. Overall, results from this study support further
investigation and optimization of SV dosing and delivery
strategies to serve as a preventative therapy for elbow PTJC.
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